



## Living Cell Technologies Limited

**CAN:** 104 028 042  
**ASX:** LCT  
**OTCQX:** LVCLY

### ASX ANNOUNCEMENT

#### Appendix 4C Quarterly Cash Flow Report 31 March 2013

**29 April 2013 – Sydney, Australia & Auckland, New Zealand** – Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 31 March 2013. The Appendix 4C is attached.

Dr Andrea Grant, Managing Director, said the company is in a solid cash position.

“Our cash balance has increased to \$4,906,000 from \$2,354,000 last quarter. We received service fees from Diatranz Otsuka Limited for R&D on DIABECELL and our expenditure on the clinical program of NTCELL in Parkinson’s was fully reimbursed by Otsuka Pharmaceutical Factory. So our cash burn in the quarter and going forward will be minimal,” said Dr Grant.

Net operating cash flow in the quarter was \$2,553,000 compared to (\$586,000) last quarter. Receipts from customers were \$4,808,000 (last quarter \$1,767,000). The prime reason for the increase in these items is the receipt of the \$3,000,000 option fee less a \$150,000 withholding tax from Otsuka Pharmaceutical Factory, Inc.

Operating payments were \$2,289,000 compared to \$2,384,000 last quarter. Approximately 85% of these payments are recovered through LCT’s co-development and joint venture agreements as they include costs for NTCELL<sup>®</sup> clinical development and the services provided to DOL for the development of DIABECELL<sup>®</sup>.

– Ends –

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the company:</b> Dr Andrea Grant Managing Director Tel: +64 9 270 7941 Mobile: +64 21 078 5421 <a href="mailto:agrant@lctglobal.com">agrant@lctglobal.com</a></p> <p>John Cowan Head of Finance &amp; Administration Tel: +64 9 276 2690 Mobile: +64 21 469000 <a href="mailto:jcowan@lctglobal.com">jcowan@lctglobal.com</a></p>	<p><b>Media enquiries:</b> Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 <a href="mailto:rachaelj@botica.co.nz">rachaelj@botica.co.nz</a></p>
--	---

## About Living Cell Technologies

Living Cell Technologies (LCT) is a recognised world leader in cell transplant therapeutics. It aims to improve the wellbeing of people with serious diseases by discovering, developing and commercialising breakthrough treatments that use the regenerative healing properties of naturally occurring cells.

In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) establishing the joint venture Diatranz Otsuka Limited (NZ). LCT transferred its most advanced therapeutic candidate DIABECCELL<sup>®</sup> into the joint venture, while OPF transferred \$25m to fund the final phase of development of DIABECCELL through to market approval.

DIABECCELL is in Phase IIb clinical trials in Argentina and is indicated for the treatment of people with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia. This is when a person's blood glucose falls to dangerously low levels without the person having any sign or symptom that this is happening. This can lead to sudden unconsciousness and loss of life, especially if the person is alone and does not receive immediate assistance to restore their glucose levels.

LCT's second therapeutic candidate is NTCELL<sup>®</sup>, a cell type taken from the brain which has the ability to protect, repair and regenerate damage tissues. In pre-clinical studies NTCELL has demonstrated the ability to regenerate damaged tissue and restore function in animal models of Parkinson's disease, stroke, Huntington's disease and hearing loss as well as acting generally to heal chronic wounds.

In 2012, LCT and OPF agreed to co-develop NTCELL as a treatment for Parkinson's with OPF fully funding the Phase I trials in New Zealand.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal.

### LCT disclaimer

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*